^
Association details:
| Biomarker: | WDR72 overexpression + PBRM1 mutation |
|---|---|
| Cancer: | Clear Cell Renal Cell Carcinoma |
| Drug: | Opdivo (nivolumab) (PD1 inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
PBRM1 mutation and WDR72 expression as potential combinatorial biomarker for predicting the response to Nivolumab in patients with ccRCC: a tumor marker prognostic study
Published date:
11/30/2023
Excerpt:
This study aims to propose a new biomarker to predict the response to Nivolumab in patients with ccRCC....high expression of WDR72 plus PBRM1-MUT as a combinatorial biomarker showed improved OS (HR=0.388, P=0.0026) and PFS (HR=0.39, P=0.0066) compared to low expression of WDR72 plus PBRM1-WT.
DOI:
https://doi.org/10.18632/aging.205261
